• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series
【24h】

Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series

机译：磷酸替地唑酯治疗蜂窝织炎和伤口感染的真实证据：一个病例系列

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionTedizolid phosphate 200?mg, once daily for 6?days, has recently been approved for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs) in several countries; however, clinical experience in real-life settings is currently limited. Here, we report on the use of tedizolid with an extended treatment duration for complex and severe ABSSSIs in real-world clinical settings. MethodsTwo patients with cellulitis and two patients with surgical site infection (SSI), aged 26–60?years, were treated with tedizolid phosphate 200?mg, intravenous/oral (IV/PO) or IV only, once daily at four different institutions. ResultsTwo morbidly obese patients had non-necrotizing, non-purulent severe cellulitis, which were complicated by sepsis or systemic inflammatory response syndrome plus myositis. One female patient failed on first-line empiric therapy with IV cefalotin, clindamycin and imipenem (3–4?days), and was switched to IV/PO tedizolid (7?+?5?days). One male patient received IV clindamycin plus IV/PO tedizolid (5?+?5?days), but clindamycin was discontinued on Day 3 due to an adverse event. For both patients, clinical signs and symptoms improved within 72?h, and laboratory results were normalized by Days 7 and 8, respectively. Two other patients (one obese, diabetic female with chronic hepatitis and chronic obstructive pulmonary disease) had complicated SSIs occurring 10?days after hernia repair with mesh or 3?months after spinal fusion surgery with metal implant. First patient with previous methicillin-resistant Staphylococcus aureus (MRSA) bacteremia received a 7-day tedizolid IV course empirically. The second patient with culture-confirmed MRSA infection received a 14-day IV course. Both patients responded within 72?h, and local and systemic signs normalized by end of treatment. There were no reports of thrombocytopenia. ConclusionTedizolid phosphate 200?mg for 7–14?days was a favored treatment option for patients with severe/complex ABSSSIs, and was effective following previous treatment failure or in late-onset infections. FundingEditorial assistance and the article processing charges were funded by Bayer AG, Berlin, Germany.
机译：前言每天200mg的替硝唑磷酸盐，每天一次，持续6天，最近在一些国家被批准用于治疗患有急性细菌性皮肤和皮肤结构感染（ABSSSI）的患者。但是，目前在现实生活中的临床经验有限。在这里，我们报告了在现实世界的临床环境中对复杂和严重的ABSSSIs使用延长治疗时间的tedizolid的情况。方法对两名年龄在26至60岁的蜂窝织炎患者和两名外科手术部位感染（SSI）患者（年龄在26-60岁之间）分别在四个不同的机构分别接受200毫克的替硝唑磷酸盐，静脉/口服（IV / PO）或IV的治疗。结果2例病态肥胖患者无坏死，无化脓性严重蜂窝组织炎，并发败血症或全身性炎症反应综合征加肌炎。一名女性患者在一线经验疗法中用头孢洛汀，克林霉素和亚胺培南静脉注射失败（3-4天），并改用静脉注射/替丁索定（7？+？5？天）。一名男性患者接受了静脉注射克林霉素加静脉注射/替丁唑治疗（5？+？5？天），但由于不良事件，克林霉素在第3天停药。对于这两名患者，其临床体征和症状均在72 h内得到改善，实验室结果分别在第7天和第8天恢复了正常。另外两名患者（一名肥胖，患有慢性肝炎和慢性阻塞性肺疾病的糖尿病女性）在疝修补网片后10天或金属植入物脊柱融合手术后3个月出现了复杂的SSI。第一例先前有耐甲氧西林的金黄色葡萄球菌（MRSA）菌血症的患者凭经验接受了为期7天的泰替唑德IV疗程。第二例经文化确认的MRSA感染的患者接受了为期14天的IV疗程。两名患者均在72小时内有反应，治疗结束后局部和全身症状恢复正常。没有血小板减少的报道。结论200毫克的替泰唑酯治疗7-14天是重症/复杂性ABSSSI患者的首选治疗方法，在先前的治疗失败或迟发感染后有效。资金编辑帮助和物品加工费由德国柏林的拜耳公司提供。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号